Defining At-Risk Populations for Parkinson's Disease: Lessons From Ongoing Studies
Identifieur interne : 000225 ( PascalFrancis/Checkpoint ); précédent : 000224; suivant : 000226Defining At-Risk Populations for Parkinson's Disease: Lessons From Ongoing Studies
Auteurs : Daniela Berg [Allemagne] ; Ken Marek [États-Unis] ; George W. Ross [États-Unis] ; Werner Poewe [Autriche]Source :
- Movement disorders [ 0885-3185 ] ; 2012.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
It is currently widely acknowledged that the natural history of PD includes a preclinical phase, and there are increasing efforts to identify markers that would allow the identification of individuals at risk for PD. Here, we discuss the issues related to defining at-risk populations for PD and review findings of current population-based cohorts that have reported potential biomarkers for PD, such as the Honolulu-Asia Aging Study (HAAS) and the PRIPS (Prospective Validation of Risk factors for the development of Parkinson Syndromes) study. We also discuss enriched risk cohorts designed to evaluate specificity and predictive value of markers exemplified by the PARS (Parkinson Associated Risk Study) and the TREND (Tubinger evaluation of Risk factors for the Early detection of NeuroDegeneration) study. Although there is still a long way to go, studies designed according to these concepts might eventually provide sufficient data to form the basis for future screening programs for PD risk to be applied at a population level.
Affiliations:
- Allemagne, Autriche, États-Unis
- Bade-Wurtemberg, Connecticut, District de Tübingen, Hawaï, Tyrol (Land)
- Innsbruck, Tübingen
- Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:12-0223365Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Defining At-Risk Populations for Parkinson's Disease: Lessons From Ongoing Studies</title><author><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute of Clinical Brain Research and German Center of Neurodegenerative Diseases, University of Tübingen</s1><s2>Tübingen</s2><s3>DEU</s3><sZ>1 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Tübingen</settlement></placeName></affiliation></author><author><name sortKey="Marek, Ken" sort="Marek, Ken" uniqKey="Marek K" first="Ken" last="Marek">Ken Marek</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Institute for Neurodegenerative Disorders</s1><s2>New Haven, Connecticut</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Ross, George W" sort="Ross, George W" uniqKey="Ross G" first="George W." last="Ross">George W. Ross</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>VA Pacific Islands Health Care System, Honolulu, Hawaii, USA, and Kuakini Medical Center</s1><s2>Honolulu, Hawaii</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Hawaï</region></placeName></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, University of Innsbruck</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>4 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0223365</idno><date when="2012">2012</date><idno type="stanalyst">PASCAL 12-0223365 INIST</idno><idno type="RBID">Pascal:12-0223365</idno><idno type="wicri:Area/PascalFrancis/Corpus">000202</idno><idno type="wicri:Area/PascalFrancis/Curation">002B12</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000225</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Defining At-Risk Populations for Parkinson's Disease: Lessons From Ongoing Studies</title><author><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute of Clinical Brain Research and German Center of Neurodegenerative Diseases, University of Tübingen</s1><s2>Tübingen</s2><s3>DEU</s3><sZ>1 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Tübingen</settlement></placeName></affiliation></author><author><name sortKey="Marek, Ken" sort="Marek, Ken" uniqKey="Marek K" first="Ken" last="Marek">Ken Marek</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Institute for Neurodegenerative Disorders</s1><s2>New Haven, Connecticut</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Ross, George W" sort="Ross, George W" uniqKey="Ross G" first="George W." last="Ross">George W. Ross</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>VA Pacific Islands Health Care System, Honolulu, Hawaii, USA, and Kuakini Medical Center</s1><s2>Honolulu, Hawaii</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Hawaï</region></placeName></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, University of Innsbruck</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>4 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Asymptomatic</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Risk factor</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Facteur risque</term><term>Asymptomatique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">It is currently widely acknowledged that the natural history of PD includes a preclinical phase, and there are increasing efforts to identify markers that would allow the identification of individuals at risk for PD. Here, we discuss the issues related to defining at-risk populations for PD and review findings of current population-based cohorts that have reported potential biomarkers for PD, such as the Honolulu-Asia Aging Study (HAAS) and the PRIPS (Prospective Validation of Risk factors for the development of Parkinson Syndromes) study. We also discuss enriched risk cohorts designed to evaluate specificity and predictive value of markers exemplified by the PARS (Parkinson Associated Risk Study) and the TREND (Tubinger evaluation of Risk factors for the Early detection of NeuroDegeneration) study. Although there is still a long way to go, studies designed according to these concepts might eventually provide sufficient data to form the basis for future screening programs for PD risk to be applied at a population level.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>27</s2></fA05><fA06><s2>5</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Defining At-Risk Populations for Parkinson's Disease: Lessons From Ongoing Studies</s1></fA08><fA09 i1="01" i2="1" l="ENG"><s1>Prodromal Parkinson's Disease</s1></fA09><fA11 i1="01" i2="1"><s1>BERG (Daniela)</s1></fA11><fA11 i1="02" i2="1"><s1>MAREK (Ken)</s1></fA11><fA11 i1="03" i2="1"><s1>ROSS (George W.)</s1></fA11><fA11 i1="04" i2="1"><s1>POEWE (Werner)</s1></fA11><fA12 i1="01" i2="1"><s1>BERG (Daniela)</s1><s9>ed.</s9></fA12><fA12 i1="02" i2="1"><s1>POEWE (Werner)</s1><s9>ed.</s9></fA12><fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute of Clinical Brain Research and German Center of Neurodegenerative Diseases, University of Tübingen</s1><s2>Tübingen</s2><s3>DEU</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Institute for Neurodegenerative Disorders</s1><s2>New Haven, Connecticut</s2><s3>USA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>VA Pacific Islands Health Care System, Honolulu, Hawaii, USA, and Kuakini Medical Center</s1><s2>Honolulu, Hawaii</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Neurology, University of Innsbruck</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>4 aut.</sZ></fA14><fA15 i1="01"><s1>Department of Neurodegeneration, Hertie Institute of Clinical Brain Research and German Center of Neurodegenerative Diseases (DZNE), University of Tübingen</s1><s2>Tübingen</s2><s3>DEU</s3><sZ>1 aut.</sZ></fA15><fA15 i1="02"><s1>Department of Neurology, University of Innsbruck</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>2 aut.</sZ></fA15><fA20><s1>656-665</s1></fA20><fA21><s1>2012</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000506918320080</s5></fA43><fA44><s0>0000</s0><s1>© 2012 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>39 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>12-0223365</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>It is currently widely acknowledged that the natural history of PD includes a preclinical phase, and there are increasing efforts to identify markers that would allow the identification of individuals at risk for PD. Here, we discuss the issues related to defining at-risk populations for PD and review findings of current population-based cohorts that have reported potential biomarkers for PD, such as the Honolulu-Asia Aging Study (HAAS) and the PRIPS (Prospective Validation of Risk factors for the development of Parkinson Syndromes) study. We also discuss enriched risk cohorts designed to evaluate specificity and predictive value of markers exemplified by the PARS (Parkinson Associated Risk Study) and the TREND (Tubinger evaluation of Risk factors for the Early detection of NeuroDegeneration) study. Although there is still a long way to go, studies designed according to these concepts might eventually provide sufficient data to form the basis for future screening programs for PD risk to be applied at a population level.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Facteur risque</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Risk factor</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Factor riesgo</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Asymptomatique</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Asymptomatic</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Asintomático</s0><s5>10</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>170</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Allemagne</li><li>Autriche</li><li>États-Unis</li></country><region><li>Bade-Wurtemberg</li><li>Connecticut</li><li>District de Tübingen</li><li>Hawaï</li><li>Tyrol (Land)</li></region><settlement><li>Innsbruck</li><li>Tübingen</li></settlement><orgName><li>Université de médecine d'Innsbruck</li></orgName></list><tree><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name></region></country><country name="États-Unis"><region name="Connecticut"><name sortKey="Marek, Ken" sort="Marek, Ken" uniqKey="Marek K" first="Ken" last="Marek">Ken Marek</name></region><name sortKey="Ross, George W" sort="Ross, George W" uniqKey="Ross G" first="George W." last="Ross">George W. Ross</name></country><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000225 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000225 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:12-0223365
|texte= Defining At-Risk Populations for Parkinson's Disease: Lessons From Ongoing Studies
}}
| This area was generated with Dilib version V0.6.23. |  |